Key Takeaways From Myriad Genetics Analyst Ratings
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Myriad Genetics (NASDAQ:MYGN) over the past three months, with recent evaluations showing a shift towards more positive outlooks. The average 12-month price target has increased to $28.0, with a high estimate of $35.00 and a low estimate of $20.00. Key analysts have adjusted their ratings and price targets, reflecting their updated expectations for the company's performance.
June 27, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided mixed ratings for Myriad Genetics (NASDAQ:MYGN) over the past three months, with recent evaluations showing a shift towards more positive outlooks. The average 12-month price target has increased to $28.0, with a high estimate of $35.00 and a low estimate of $20.00. Key analysts have adjusted their ratings and price targets, reflecting their updated expectations for the company's performance.
The recent shift in analyst ratings towards more positive outlooks and the increase in the average 12-month price target suggest a potential short-term positive impact on MYGN's stock price. Key analysts have raised their price targets, indicating improved expectations for the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100